Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Discovery

• Publication date

  2014-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-13-0286PMID 24356096PMCID PMC3946308
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Actionable Therapeutic Targets Breast Cancers after Neoadjuvant Chemotherapy Identifies Molecular Profiling of the Residual Disease of Triple-Negative

  2014cited by this paper
• R: A language and environment for statistical computing.

  2014cited by this paper
• Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.

  2013cited by this paper
• Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

  2013cited by this paper
• Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells

  2013cited by this paper
• Programming cancer cells for high expression levels of Mcl1

  2013cited by this paper
• TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

  2013cited by this paper
• A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer

  2013cited by this paper
• Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

  2012cited by this paper
• Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

  2012cited by this paper
• Genome Sequencing Identifies a Basis for Everolimus Sensitivity

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• The clonal and mutational evolution spectrum of primary triple-negative breast cancers

  2012cited by this paper
• Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

  2012influential reference
• Absolute quantification of somatic DNA alterations in human cancer

  2012cited by this paper
• C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway.

  2012cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• A framework for variation discovery and genotyping using next-generation DNA sequencing data

  2011cited by this paper
• Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients

  2011cited by this paper
• Why are de Bruijn graphs useful for genome assembly?

  2011cited by this paper
• Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• SCFFBW 7 regulates cellular apoptosis by targeting MCL 1 for ubiquitylation and destruction

  2011cited by this paper
• SCFFbw7 Regulates Cellular Apoptosis By Targeting Mcl-1 for Ubiquitination and Destruction

  2010cited by this paper
• A clinically relevant gene signature in triple negative and basal-like breast cancer

  2010cited by this paper
• Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

  2010cited by this paper
• A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data

  2010cited by this paper
• Allele-specific copy number analysis of tumors

  2010cited by this paper
• p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

  2009cited by this paper
• The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

  2009cited by this paper
• A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.

  2009cited by this paper
• MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family

  2009cited by this paper
• The Sequence Alignment/Map format and SAMtools

  2009cited by this paper
• Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4.

  2008cited by this paper
• Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells

  2008cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

  2006cited by this paper
• IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A

  2005cited by this paper
• Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells.

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

  2000cited by this paper
• American Association for Cancer Research

  2000cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• BIOINFORMATICS ORIGINAL PAPER

  year unknowncited by this paper

• Resistance to neoadjuvant chemotherapy in breast cancers: a metabolic perspective

  2025cites this paper
• Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer

  2025cites this paper
• A novel synthesised STAT3 inhibitor exerts potent anti‐tumour activity by inducing lysosome‐dependent cell death

  2025cites this paper
• MYC/TET3‐Regulated TMEM65 Activates OXPHOS‐SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple‐Negative Breast Cancer

  2025cites this paper
• KDM4C shields breast cancer from the histone scissor cathepsin L

  2025cites this paper
• Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment.

  2025cites this paper
• Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer

  2025cites this paper
• CDK16+ Luminal Progenitor Cell‐Like Tumor Cells Interacted with POSTN+ Cancer‐Associated Fibroblasts Associate with Chemo‐Resistance In Breast Cancer

  2025cites this paper
• Challenging triple negative breast cancer through HDAC6 selective inhibition: Novel cap-group identification, structure-activity relationships, computational and biological studies.

  2025cites this paper
• Role of MYC inhibition in overcoming resistance to HER2-targeted therapies for breast cancer.

  2025cites this paper
• An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant Chemotherapy.

  2025cites this paper
• Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications

  2025cites this paper
• Impact of hormone receptor and HER2 conversions on survival after neoadjuvant chemotherapy in breast cancer patients

  2025cites this paper
• Inhibition of MCL-1 and MEK overcomes MEK inhibitor resistance in triple-negative and inflammatory breast cancers.

  2025cites this paper
• Minimal residue disease detection in early-stage breast cancer: a review

  2025cites this paper
• Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations

  2025cites this paper
• Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine

  2025cites this paper
• Discovery of a novel BCL-2 inhibitor GW806742X for the treatment of TNBC.

  2025cites this paper
• Antineoplastic effect of compounds C14 and P8 on TNBC and radioresistant TNBC cells by stabilizing the K-Ras4BG13D/PDE6δ complex

  2024cites this paper
• An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer

  2024cites this paper
• Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion

  2024cites this paper
• Integrated Proteogenomic Analysis Reveals Distinct Potentially Actionable Therapeutic Vulnerabilities in Triple-Negative Breast Cancer Subtypes

  2024cites this paper
• Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer

  2024cites this paper
• Dual Inhibition of the TrkA and JAK2 pathways using Entrectinib and Pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.

  2024cites this paper
• Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth

  2024cites this paper
• EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer

  2024cites this paper
• Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer.

  2024cites this paper
• Basal–epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer

  2024cites this paper
• Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer

  2024influential citation
• Stress in the metastatic journey – the role of cell communication and clustering in breast cancer progression and treatment resistance

  2024cites this paper
• Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers

  2024cites this paper
• Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isoform!

  2024cites this paper
• High BMI Is Associated with Changes in Peritumor Breast Adipose Tissue That Increase the Invasive Activity of Triple-Negative Breast Cancer Cells

  2024cites this paper
• CDK9 inhibitors for the treatment of solid tumors.

  2024cites this paper
• Mitochondrial bioenergetics of breast cancer.

  2024cites this paper
• Characterization of BCL-XL, MCL-1, and BAX Protein Expression in Response to Neoadjuvant Chemotherapy in Breast Cancer

  2024cites this paper
• Enhanced expression of galectin‐9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy

  2024cites this paper
• Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors

  2023cites this paper
• Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice

  2023cites this paper
• New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1.

  2023cites this paper
• Identification of a core EMT signature that separates basal-like breast cancers into partial- and post-EMT subtypes

  2023cites this paper
• Overview of the therapeutic strategies for ER positive breast cancer.

  2023cites this paper
• Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple‐negative breast cancer (TNBC)

  2023cites this paper
• Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer

  2023cites this paper
• Research on the Effects of Chemotherapy on Survival Outcomes for Older Patients with Primary Triple-Negative Breast Cancer after Surgery: A Propensity Score Matching and Competing Risk Analysis of the SEER Database

  2023cites this paper
• Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer

  2023cites this paper
• Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital

  2023cites this paper
• Association of Augmented Immune-Staining of G-Quadruplex Tertiary DNA Structure in Chemo-Tolerant TNBC with Downregulation of WNT/Epidermal Growth Factor Receptor Pathway receptor Genes: A Pilot Clinicopathological Study

  2023cites this paper
• Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges

  2023cites this paper
• Crosstalk between triple negative breast cancer and microenvironment

  2023cites this paper
• Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications

  2023cites this paper
• Rewiring of mitochondrial metabolism in therapy-resistant cancers: permanent and plastic adaptations

  2023cites this paper
• Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC

  2023cites this paper
• Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

  2023cites this paper
• Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer

  2023cites this paper
• Troponin T1 silencing inhibits paclitaxel resistance and the development of breast cancer via suppressing rat sarcoma virus/rapidly accelerated fibrosarcoma 1 pathway

  2023cites this paper
• Dormancy in Breast Cancer.

  2023cites this paper
• Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care

  2023cites this paper
• Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: propensity score matching and inverse probability of treatment weighting analysis

  2023influential citation
• Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA

  2023cites this paper
• Tetrazole and acylsulfonamide bioisosteric replacements of the carboxylic acid in a dual MCL-1/BCL-xL inhibitor are tolerated

  2023cites this paper
• Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation

  2023cites this paper
• Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family.

  2023cites this paper
• The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers

  2023cites this paper
• Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma

  2023cites this paper
• Tumor‐infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer

  2023influential citation
• Implications of tumour heterogeneity on cancer evolution and therapy resistance: lessons from breast cancer

  2023cites this paper
• 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) induces apoptosis in breast cancer cells through inhibiting of Mcl-1 expression

  2023cites this paper
• Prognostic value of RGS1 and mTOR Immunohistochemical expression in Egyptian multiple myeloma patients; A single center study

  2023influential citation
• A global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data

  2023cites this paper
• NOXA/MCL-1 axis determines cell-death decision between apoptosis and pyroptosis and the inflammatory secretome of breast cancer cells treated with anti-mitotics

  2023cites this paper
• Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability

  2023cites this paper
• Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy

  2023cites this paper
• Targeting MCL-1 protein to treat cancer: opportunities and challenges

  2023cites this paper
• Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer

  2023cites this paper
• Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer

  2023cites this paper
• High-throughput screening of ancient forest plant extracts shows cytotoxicity towards triple-negative breast cancer.

  2023cites this paper
• Integration of multi-omics data shows downregulation of mismatch repair, purin, and tublin pathways in AR-negative triple-negative chemotherapy-resistant breast tumors

  2022cites this paper
• Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.

  2022cites this paper
• Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer.

  2022cites this paper
• Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance

  2022cites this paper
• Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer

  2022cites this paper
• First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.

  2022cites this paper
• Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase

  2022influential citation
• Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications.

  2022cites this paper
• MCL-1 is a clinically targetable vulnerability in breast cancer

  2022cites this paper
• Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular Subtypes of Breast Cancer

  2022cites this paper
• Targeting Apoptosis in Cancer

  2022cites this paper
• Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC

  2022cites this paper
• Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer

  2022cites this paper
• Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer

  2022cites this paper
• Update on triple‐negative breast cancers – highlighting subtyping update and treatment implication

  2022cites this paper
• Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis

  2022cites this paper
• Novel markers in breast pathology

  2022cites this paper
• Identifying mechanisms driving the early response of triple negative breast cancer patients to neoadjuvant chemotherapy using a mechanistic model integrating in vitro and in vivo imaging data

  2022cites this paper
• COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy

  2022cites this paper
• The role of MEOX1 in non-neoplastic and neoplastic diseases.

  2022cites this paper
• JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States

  2022cites this paper
• Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer

  2022cites this paper
• The Predictive and Prognostic Role of RAS–RAF–MEK–ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets

  2022cites this paper